The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

The following article, which first saw the light of day in May 2014, is an example of why there can more to a story than ...

The following article, which first appeared in The Post-Journal in May 2014, is an example of why there can more to a story ...

A family is preparing for three fundraising challenges in memory of their husband and dad who received treatment at an Oxford hospital.

"Woman," "elderly," and "disabled" were among a list of banned words reportedly circulating within the FDA, which the White ...

Shannin Desroches fought for a diagnosis after being dismissed. Now she tells PEOPLE that she's been given a 5% chance of ...

The Metropolitan Opera will double cast a portion of Verdi and Puccini revivals and shift some contemporary compositions away ...

Hundreds of Washington students, parents, teachers and other educators demonstrated at the state Capitol on Monday, calling for increased funding for the state’s public school system.

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...

The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture ...

Dr. Greg Vigna Debridement for decubitus ulcers must align with treatment goals, with early reconstructive surgery recommended to avoid ris ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...